INSULIN RESISTANCE IN MOOD DISORDERS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 20世纪上半叶的文献表明，严重的精神疾病与糖尿病或葡萄糖不耐受之间存在联系。患有严重情绪障碍的患者增加风险的机制尚不清楚，但糖皮质激素升高、交感神经系统激活、喂养行为失调、自我照顾不良、吸烟或饮酒等共病以及社会人口风险因素如社会经济地位低、获得医疗保健的机会较少以及社会支持不足等被认为会增加体重增加、胰岛素抵抗和2型糖尿病的风险。同时患有情绪障碍和糖尿病或胰岛素抵抗的患者的认知缺陷更大。本研究旨在检测胰岛素抵抗对抑郁症患者神经认知测量的影响，在基线和胰岛素增敏药物(二甲双胍)治疗90天后再次进行。我们假设，根据对葡萄糖耐量测试的反应，胰岛素抵抗水平高的参与者将表现出更大的认知缺陷。此外，我们假设，胰岛素抵抗的参与者在接受胰岛素增敏药物治疗后，认知能力会有所改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Literature from the first part of the 20th century suggested an association between severe mental illness and diabetes or glucose intolerance. The mechanism by which patients with a major mood disorder have increased risk is not known, but elevated glucocorticoids, activation of the sympathetic nervous system, dysregulated feeding behavior, poor self care, comorbid disorders such as tobacco or alcohol use, and sociodemographic risk factors such as low socioeconomic status, poor access to health care, and poor social support, have been thought to increase the risk of weight gain, insulin resistance, and type 2 diabetes. Greater cognitive deficits are observed in patients with both mood disorders and with diabetes or insulin resistance. The present study seeks to examine the effects of insulin resistance on neurocognitive measures in depressed patients at baseline and again after 90 days of an insulin-sensitizing medication (Metformin). We hypothesize that participants with high levels of insulin resistance, as determined by response to glucose tolerance testing, will show greater cognitive deficits. Further, we hypothesize that participants with insulin resistance will demonstrate cognitive improvement after treatment with an insulin-sensitizing medication.